Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Cash & Current Investments (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Cash & Current Investments for 4 consecutive years, with $266.6 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Cash & Current Investments rose 42.35% year-over-year to $266.6 million, compared with a TTM value of $266.6 million through Sep 2023, up 42.35%, and an annual FY2022 reading of $162.9 million, down 1.85% over the prior year.
  • Cash & Current Investments was $266.6 million for Q3 2023 at Terns Pharmaceuticals, down from $285.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $285.6 million in Q2 2023 and bottomed at $11.7 million in Q1 2020.
  • Average Cash & Current Investments over 4 years is $154.7 million, with a median of $166.0 million recorded in 2021.
  • The sharpest move saw Cash & Current Investments surged 1572.2% in 2021, then fell 24.46% in 2022.
  • Year by year, Cash & Current Investments stood at $74.9 million in 2020, then surged by 121.74% to $166.0 million in 2021, then decreased by 1.85% to $162.9 million in 2022, then surged by 63.65% to $266.6 million in 2023.
  • Business Quant data shows Cash & Current Investments for TERN at $266.6 million in Q3 2023, $285.6 million in Q2 2023, and $282.6 million in Q1 2023.